CRD 102 - Cardiora

Drug Profile

CRD 102 - Cardiora

Alternative Names: CRD-102 - Cardiora

Latest Information Update: 17 Jun 2016

Price : $50

At a glance

  • Originator Cardiora
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 16 Jun 2016 Preclinical trials in Heart failure in USA (PO) before June 2016 (Cardiora website, June 2016)
  • 16 Jun 2016 Cardiora plans to file an IND application with the US FDA for Heart faliure in the fourth quarter of 2016 (Cardiora website, June 2016)
  • 12 May 2016 Cardiora initiates enrolment in a phase Ib trial for Heart faliure in Australia (ACTRN12616000619448p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top